论文部分内容阅读
【目的】研究新生儿呼吸衰竭的病因及发病因素,探讨肺表面活性物质(pulmonary surfactant,PS)联合辅助通气在新生儿呼吸衰竭中的治疗效果。【方法】回顾性分析2010年7月-2011年7月遵义市第一人民医院新生儿科收治的121例新生儿呼吸衰竭患儿的病例资料,所有病例均给予呼吸支持为主的综合治疗,联合应用肺表面活性物质的49例为试验组,同期单用辅助通气治疗的72例为对照组,比较两组患儿的辅助通气持续时间、总氧疗时间、治愈率、死亡率及并发症发生率。【结果】试验组的治愈率(89.8%)高于对照组(69.4%),死亡率低于对照组(χ2=7.16,P<0.05);试验组的辅助通气持续时间及总氧疗时间明显低于对照组(U=20.979和12.997,P均<0.01);两组的并发症发生率差异无统计学意义(P均>0.05)。【结论】肺表面活性物质联合辅助通气为主的综合治疗可明显提高呼吸衰竭患儿的治愈率,同时不增加并发症的发生率。
【Objective】 To investigate the etiology and pathogenesis of respiratory failure in neonates and to explore the therapeutic effect of pulmonary surfactant (PS) combined with assisted ventilation in neonatal respiratory failure. 【Methods】 A retrospective analysis was conducted on 121 cases of neonatal respiratory failure in the First People’s Hospital of Zunyi from July 2010 to July 2011. All the cases were given comprehensive treatment of respiratory support. Forty-nine patients with pulmonary surfactant were used as the experimental group, and 72 patients treated with supplemental ventilation during the same period as the control group. The duration of auxiliary ventilation, total oxygen therapy time, cure rate, mortality and complications were compared between the two groups rate. 【Results】 The cure rate of the experimental group (89.8%) was higher than that of the control group (69.4%) and the mortality rate was lower than that of the control group (χ2 = 7.16, P <0.05). The duration of auxiliary ventilation and total oxygen therapy time Lower than the control group (U = 20.979 and 12.997, P <0.01). There was no significant difference in the complication rates between the two groups (all P> 0.05). 【Conclusion】 The combination therapy of pulmonary surfactant and assisted ventilation can significantly improve the cure rate of children with respiratory failure without increasing the incidence of complications.